WALTHAM, Mass., Feb. 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2008 results, along with guidance for 2009, on Thursday, February 26, 2009 . A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EST (1:30 p.m. PST).
To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations."
OXiGENE's earnings conference call can also be heard live by dialing (877) 856-1965 in the United States and Canada, and (719) 325-4798 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. ET, (4:30 p.m. PST) on February 26, 2009 and ending at 7:30 p.m. ET (4:30 p.m. PST) on Thursday, March 12, 2009. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 2203249.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969